PaySign, Inc. provides financial guidance for the second quarter of 2024 and maintains financial guidance for the full year of 2024. For the second quarter, the company expects total revenue to increase by approximately 27.5% over the second quarter of 2023 with pharma revenue accounting for approximately 18.0% of the total.

For the full-year, based on the first quarter financial results and financial expectations for the remainder of the year, the company is confirming the guidance it gave in March 2024, for total revenues to be in the range of $54.5 million to $56.7 million.